MariMed (MRMD) CCO nets shares after 12,500 RSU vesting and tax withholding

Rhea-AI Filing Summary

MariMed Inc. Chief Commercial Officer Ryan Crandall reported equity compensation activity involving restricted stock units (RSUs) that convert to common shares on a one-for-one basis. On the reported date, 12,500 RSUs were exercised into 12,500 shares of common stock at no cash exercise price.

To satisfy tax withholding obligations tied to this RSU vesting, 4,332 common shares were withheld by the company. After these transactions, Crandall’s direct ownership in MariMed common stock stood at 875,683 shares.

Insider Trade Summary

12,500 shares exercised/converted

Mixed 3 txns

Insider Crandall Ryan

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units (RSU)	12,500	$0.00	--
Exercise	Common stock	12,500	$0.00	--
Tax Withholding	Common stock	4,332	$0.084	$363.89

Holdings After Transaction: Restricted Stock Units (RSU) — 0 shares (Direct); Common stock — 880,015 shares (Direct)

Footnotes (1)

1. RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. These RSUs were granted on March 7, 2023; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crandall Ryan

(Last) (First) (Middle)

10 OCEANA WAY, 2ND FLOOR

(Street)

NORWOOD MA 02062

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	03/07/2026		M		12,500	A	$0(1)	880,015	D
Common stock	03/07/2026		F		4,332(2)	D	$0.084	875,683	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	03/07/2026		M			12,500	(3)	(3)	Common Stock, par value $.001 per share	12,500	$0	0	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. These RSUs were granted on March 7, 2023; there are no unvested RSUs remaining under this grant in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Ryan Crandall	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MariMed (MRMD) report for Ryan Crandall?

MariMed Chief Commercial Officer Ryan Crandall exercised 12,500 restricted stock units into 12,500 common shares. As part of this equity compensation event, a portion of the resulting shares was withheld to cover associated tax obligations, with the remainder increasing his direct share ownership.

How many MariMed (MRMD) RSUs did Ryan Crandall convert to common stock?

Ryan Crandall converted 12,500 restricted stock units into 12,500 shares of MariMed common stock on a one-for-one basis. This derivative exercise reflected the scheduled vesting terms of his prior RSU grant under an award agreement with the company.

Were any MariMed (MRMD) shares sold on the market in this Form 4?

The Form 4 shows 4,332 MariMed common shares were disposed of to satisfy tax withholding obligations related to RSU vesting. This is characterized as a tax-withholding disposition, not an open-market sale initiated for investment or trading purposes.

What is Ryan Crandall’s MariMed (MRMD) share ownership after the RSU vesting?

Following the RSU conversion and related tax withholding, Ryan Crandall directly holds 875,683 shares of MariMed common stock. This figure reflects his updated post-transaction ownership reported in the Form 4 as of the transaction date.

How were taxes handled on Ryan Crandall’s MariMed (MRMD) RSU vesting?

To cover tax withholding obligations arising from the vesting of RSUs, 4,332 MariMed common shares were withheld by the company. This method uses a portion of vested shares instead of a separate cash payment for the tax liability.